Transcatheter Embolization and Occlusion Devices – Market Insights – United States

The US TEO device market will expand at a moderate rate over the forecast period after recovering from the impact of COVID-19. The market factors contributing to this growth will include the continued adoption of minimally invasive treatments, launch of innovative new products in the liquid embolic and flow-diverting device segments, and expanding treatment indications for existing products.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for TEO devices in the US from 2019 through 2032.

The COVID-19 pandemic had short term consequences on the interventional oncology device market.

Which procedures were most impacted by the pandemic?

What has recovery looked like among the different procedure categories covered?

Flow-diverting devices and intrasaccular devices continue to see strong adoption.

How has the competitive landscape changed with the emergence of new competitors and products?

How will the adoption of neurovascular flow-diverting devices impact the neurovascular embolization coil and coiling-assist device markets?

Which strategies are competitors adopting to gain a competitive edge over other competitors in the neurovascular flow-diverting device market?

Liquid embolics are gaining traction as technologies are approved for new indications.

How will the approval of new liquid embolics influence their adoption?

For which indications have products been approved?

Table of contents